NEW YORK (AP) – European Union regulators approved a new treatment for lupus produced by Human Genome Sciences Inc. and GlaxoSmithKline PLC, the companies said.
Benlysta received marketing approval as a treatment for lupus in patients who have not been helped by standard therapies. The Food and Drug Administration approved the drug in March, and Canadian regulators cleared it in Tuesday. Human Genome Sciences and GlaxoSmithKline said regulators in nine other countries, including Russia and Brazil, are reviewing Benlysta.
Date: July 14, 2011
Source: Associated Press
Filed Under: Drug Discovery
